ValueScreener

ValueScreener company report

Universe Pharmaceuticals Inc. (UPC)

NASDAQ / Healthcare / Drug Manufacturers - Specialty & Generic

Share price

4.15 USD Market dataClose of Oct 15, 2026

Market capitalisation

2.6M USD Market dataClose of Oct 15, 2026
Market data
Oct 15, 2026
Filed accounts
FY2025, filed Jan 29, 2026
Ratios computed
Oct 15, 2026
Filed years
7, FY2019 to FY2025
Four kinds of sourceSEC filingCompany statementMarket dataComputedWhat each means
SEC filingFiled with the SEC
Read from a statement the company filed with the SEC, with the form, fiscal year, filing date and accession beside it.
Company statementCompany statement
What the company says about itself in a filing: an 8-K item, the auditor, its own segment names.
Market dataMarket data
Prices, market value and what analysts publish, with the date they are as of.
ComputedComputed by ValueScreener
Worked out by us from the other three, with the inputs and the formula one press away. A score is a research output, not a rating or a recommendation.
Reading

1 of 10

Overview

What the business is, what it costs, and how it reads on four questions.

Market dataSEC filingComputed

Four questions, at a glance

Quality

Return on equity

-6.5% Computed

From the FY2025 filing

Read quality

Valuation

Price to earnings

n/m Computed

FY2025 accounts, priced at the latest close

Why n/m

Earnings are zero or negative, so a price to earnings multiple is not meaningful. A negative P/E is not a cheap company and a large positive one from a near-zero denominator is not an expensive one.

Read valuation

Cash generation

Free cash flow yield

n/m Computed

FY2025 accounts, priced at the latest close

Why n/m

Not meaningful for this company, such as a P/E on negative earnings or a bank's EV/EBIT.

Read cash generation

Revenue and net income, by fiscal year

FY2018 Revenue: 28.5M USDFY2018 Net income: 7.6M USDFY2019 Revenue: 33.2M USDFY2019 Net income: 7.6M USDFY2020 Revenue: 30.7M USDFY2020 Net income: 7.6M USDFY2021 Revenue: 48.0M USDFY2021 Net income: 11.3M USDFY2022 Revenue: 40.1M USDFY2022 Net income: -7.9M USDFY2023 Revenue: 32.31B USDFY2023 Net income: -6.58B USDFY2024 Revenue: 23.02B USDFY2024 Net income: -8.73B USDFY2025 Revenue: 17.86B USDFY2025 Net income: -3.67B USD
Revenue Net income8 fiscal years; a year whose statement names no SEC filing is market data, and the table in Filings says which.
Named tests met
0 of 30 Which tests
The business, and the score behind its five axes

The reading, in brief

Is it good

Return on equity was -6.5% in FY2025, in the band labelled "Likely below the cost of equity" (below 8.0%), on lines anchored on Damodaran's cost-of-capital data, suggesting returns on shareholders' money below the usual cost of equity.

Today, against the Drug Manufacturers - Specialty & Generic industry (57 companies), -6.5% sits at the 55th percentile; the middle half of that group runs from -35.9% to 7.5%.

Is it safe

Current ratio was 4.07 in FY2025, in the band labelled "At or above Graham's requirement" (2.00 and above), on lines anchored on Graham's defensive-investor criteria, suggesting short-term assets well above short-term obligations.

Today, against the Drug Manufacturers - Specialty & Generic industry (68 companies), 4.07 sits at the 76th percentile; the middle half of that group runs from 1.36 to 4.07.

Year by year against peers
Whether Universe Pharmaceuticals Inc.'s return on equity stayed above the median of the Drug Manufacturers - Specialty & Generic industry, year by year. (FY2023 to FY2025, 3 fiscal years of Universe Pharmaceuticals Inc. with a comparable figure)
The direction
Which way Universe Pharmaceuticals Inc.'s gross margin has moved, and how steadily. (FY2018 to FY2025, 8 filed years of Universe Pharmaceuticals Inc.)
What could explain it
What in Universe Pharmaceuticals Inc.'s filed statements could explain the movements. (5 readings drawn from the statement lines Universe Pharmaceuticals Inc. filed)
What to check next
What to check next on Universe Pharmaceuticals Inc., and where in its filings. (5 questions for Universe Pharmaceuticals Inc.)
In one paragraph
One paragraph on Universe Pharmaceuticals Inc.'s returns, cash, balance sheet and price. (7 of sixteen figures read for Universe Pharmaceuticals Inc.)

These are UPC’s filed figures. The research desk says what they mean, against peers and its own years, with what to check next.

Research UPCPart of Serious. New accounts start with 30 days of Professional, free, no card.

2 of 10

What changed

The newest filing, what it moved, and when the next one is due.

SEC filingCompany statement

The newest accounts on file are the FY2025 annual report: 20-F, filed Jan 29, 2026, accession 0001213900-26-009000.

3 of 10

Quality

The returns the business earns on its capital, and the margins behind them.

SEC filingComputed

Universe Pharmaceuticals Inc: returns on capital and margins, each with its source
FigureValue, source and document
Return on invested capital, after tax
Why n/a

The debt total on file was summed from short-term debt, long-term debt and lease obligations, and at least one of those was never captured. An absent term is spent as a zero inside that sum, and this balance sheet does not show the term is empty, so we will not build a leverage ratio, an enterprise value or a return on capital on it, or rank the company on one.

n/a ComputedFY2025 20-F, filed Jan 29, 2026, 0001213900-26-009000
Return on equity-6.5% ComputedFY2025 20-F, filed Jan 29, 2026, 0001213900-26-009000
Return on capital employed, pre-tax-5.2% ComputedFY2025 20-F, filed Jan 29, 2026, 0001213900-26-009000
Return on assets-5.3% ComputedFY2025 20-F, filed Jan 29, 2026, 0001213900-26-009000
Gross margin35.3% ComputedFY2025 20-F, filed Jan 29, 2026, 0001213900-26-009000
Operating margin-16.3% ComputedFY2025 20-F, filed Jan 29, 2026, 0001213900-26-009000
Net margin-20.6% ComputedFY2025 20-F, filed Jan 29, 2026, 0001213900-26-009000
UPC -20.6%
SBFM -16.5%SNOA -16.3%YCBD -10.6%TXMD -18.8%BFRI -25.3%
-25.3%-10.6%
Net margin: UPC against the 5 companies named under Valuation context, each as filed for its own latest year. Placement only: no average is drawn.

4 of 10

Financial strength

What it owes against what it owns, and whether it can meet what falls due.

SEC filingComputedCompany statement

Universe Pharmaceuticals Inc: leverage, liquidity and distress, each with its source
FigureValue, source and document
Debt to equity
Why n/a

The debt total on file was summed from short-term debt, long-term debt and lease obligations, and at least one of those was never captured. An absent term is spent as a zero inside that sum, and this balance sheet does not show the term is empty, so we will not build a leverage ratio, an enterprise value or a return on capital on it, or rank the company on one.

n/a ComputedFY2025 20-F, filed Jan 29, 2026, 0001213900-26-009000
Current ratio4.07 ComputedFY2025 20-F, filed Jan 29, 2026, 0001213900-26-009000
Quick ratio3.90 ComputedFY2025 20-F, filed Jan 29, 2026, 0001213900-26-009000
Interest coverage
Why n/m

Operating income is zero or below, so there is no operating profit to cover the interest bill and coverage is not meaningful (n/m).

n/m ComputedFY2025 20-F, filed Jan 29, 2026, 0001213900-26-009000
Altman Z-score0.54 ComputedClose of Oct 15, 2026 · FY2025 20-F, filed Jan 29, 2026, 0001213900-26-009000
Net debt
Why n/a

The FY2025 balance sheet carries no net debt we could read.

n/a ComputedFY2025 20-F, filed Jan 29, 2026, 0001213900-26-009000
Total assets 69.30BTotal liabilities 13.17BShareholders' equity 56.13BOwnsOwes, and equity
Total assets Total liabilities Shareholders’ equity
The balance sheet, line by line

Financial health

What Universe Pharmaceuticals Inc owned and owed at the end of fiscal 2025, from the balance sheet it filed (20-F, filed Jan 29, 2026, 0001213900-26-009000).

Universe Pharmaceuticals Inc: balance sheet position
Total assets69.30B FiledFY2025 20-F, filed Jan 29, 2026
Total liabilities13.17B FiledFY2025 20-F, filed Jan 29, 2026
Shareholders' equity56.13B FiledFY2025 20-F, filed Jan 29, 2026
Cash33.59B FiledFY2025 20-F, filed Jan 29, 2026
Total debtn/a FiledFY2025 20-F, filed Jan 29, 2026
Net debtn/a
Current ratio4.07
Debt to equityn/a
  • Debt to equity: FY2025: The debt total on file was summed from short-term debt, long-term debt and lease obligations, and at least one of those was never captured. An absent term is spent as a zero inside that sum, and this balance sheet does not show the term is empty, so we will not build a leverage ratio, an enterprise value or a return on capital on it, or rank the company on one.
  • Interest cover: FY2025: Operating income is zero or below, so there is no operating profit to cover the interest bill and coverage is not meaningful (n/m).

Read from the filed balance sheet for each year, with the income statement of the same year supplying operating profit where a ratio needs it. Nothing here is a view on whether this company is sound.

5 of 10

Valuation context

What the market charges for it, against its own record and companies like it.

Market dataComputed

Universe Pharmaceuticals Inc: what the market charges, each with its source
FigureValue, source and document
Price to earnings
Why n/m

Earnings are zero or negative, so a price to earnings multiple is not meaningful. A negative P/E is not a cheap company and a large positive one from a near-zero denominator is not an expensive one.

n/m ComputedClose of Oct 15, 2026 · FY2025 20-F, filed Jan 29, 2026, 0001213900-26-009000
P/E on trailing twelve months
Why n/a

A trailing figure needs 4 filed quarters with the dates they were filed on, and we hold 0 for this company. Nothing is drawn rather than a line built from fewer.

n/a ComputedClose of Oct 15, 2026 · Trailing four quarters, each as known on the day; the quarterly filings are listed under Filings
Price to book
Why n/a

A stored zero the filing does not prove, withheld rather than published as if it were a measurement.

n/a ComputedClose of Oct 15, 2026 · FY2025 20-F, filed Jan 29, 2026, 0001213900-26-009000
Price to sales
Why n/a

A stored zero the filing does not prove, withheld rather than published as if it were a measurement.

n/a ComputedClose of Oct 15, 2026 · FY2025 20-F, filed Jan 29, 2026, 0001213900-26-009000
Enterprise value to EBIT
Why n/a

The debt total on file was summed from short-term debt, long-term debt and lease obligations, and at least one of those was never captured. An absent term is spent as a zero inside that sum, and this balance sheet does not show the term is empty, so we will not build a leverage ratio, an enterprise value or a return on capital on it, or rank the company on one.

n/a ComputedClose of Oct 15, 2026 · FY2025 20-F, filed Jan 29, 2026, 0001213900-26-009000
Enterprise value to EBITDA
Why n/m

EBITDA is zero or negative, so a multiple of it is not meaningful.

n/m ComputedClose of Oct 15, 2026 · FY2025 20-F, filed Jan 29, 2026, 0001213900-26-009000
Price to earnings over growth
Why n/m

Earnings are zero or negative, so a price to earnings multiple is not meaningful. A negative P/E is not a cheap company and a large positive one from a near-zero denominator is not an expensive one.

n/m ComputedClose of Oct 15, 2026 · FY2025 20-F, filed Jan 29, 2026, 0001213900-26-009000
Diluted earnings per share
Why n/a

The FY2025 filing carries no diluted earnings per share we could read.

n/a FiledFY2025 20-F, filed Jan 29, 2026, 0001213900-26-009000
Graham number
Why n/m

Earnings are zero or negative, so a price to earnings multiple is not meaningful. A negative P/E is not a cheap company and a large positive one from a near-zero denominator is not an expensive one.

n/m ComputedFY2025 20-F, filed Jan 29, 2026, 0001213900-26-009000

We publish no fair value or price target of our own. Value UPC on your own assumptions in the DCF workbench, starting from the filed figures.

Its own record, and companies like it

Valuation

What the market charges for Universe Pharmaceuticals Inc today, and the multiples it has carried. No value of ours: the figures are the filings’ and the market’s.

Universe Pharmaceuticals Inc: valuation
Share price4.15 USD
Market capitalisation2.6M USD
Enterprise value to EBITDAn/m
Graham numbern/m
Diluted earnings per share, FY2018n/a

Diluted earnings per share, FY2018: Filed before the 1-for-6 split on 28 Jul 2023, the 1-for-15 split on 18 Nov 2024 and the 1-for-40 split on 24 Mar 2025, and the filing it was read from cannot be placed against them, so it is not put on today's share count and is not shown beside figures that are.

Price to earnings on trailing twelve months: A trailing figure needs 4 filed quarters with the dates they were filed on, and we hold 0 for this company. Nothing is drawn rather than a line built from fewer.

Companies like Universe Pharmaceuticals Inc

  1. Sunshine Biopharma, Inc. (SBFM)Market cap 488.4K USD
  2. Sonoma Pharmaceuticals, Inc. (SNOA)Market cap 5.5M USD
  3. cbdMD, Inc. (YCBD)Market cap 4.0M USD
  4. TherapeuticsMD, Inc. (TXMD)Market cap 22.3M USD
  5. Biofrontera Inc. (BFRI)Market cap 12.6M USD

Same industry (Drug Manufacturers - Specialty & Generic) and size band (Nano, under 50M), nearest in market value, net margin and current ratio. Each of those counts equally, by how many of the companies considered sit between the two on it. Closest first: the order is likeness and nothing else.

6 of 10

Cash generation

Whether profit arrives as cash, and what is paid back to shareholders.

SEC filingComputed

Universe Pharmaceuticals Inc: cash generation and what is paid out, each with its source
FigureValue, source and document
Free cash flow yield
Why n/m

Not meaningful for this company, such as a P/E on negative earnings or a bank's EV/EBIT.

n/m ComputedClose of Oct 15, 2026 · FY2025 20-F, filed Jan 29, 2026, 0001213900-26-009000
Free cash flow-5.32B USD ComputedFY2025 20-F, filed Jan 29, 2026, 0001213900-26-009000
Free cash flow margin-29.8% ComputedFY2025 20-F, filed Jan 29, 2026, 0001213900-26-009000
Dividend yield
Why n/a

We do not hold this figure for this company, so there is nothing to show.

n/a ComputedClose of Oct 15, 2026 · FY2025 20-F, filed Jan 29, 2026, 0001213900-26-009000
Payout ratio
Why n/a

We do not hold this figure for this company, so there is nothing to show.

n/a ComputedFY2025 20-F, filed Jan 29, 2026, 0001213900-26-009000
FY2018 Free cash flow: 4.3M USDFY2018 Net income: 7.6M USDFY2019 Free cash flow: 13.1M USDFY2019 Net income: 7.6M USDFY2020 Free cash flow: 6.1M USDFY2020 Net income: 7.6M USDFY2021 Free cash flow: -2.5M USDFY2021 Net income: 11.3M USDFY2022 Free cash flow: -1.4M USDFY2022 Net income: -7.9M USDFY2023 Free cash flow: 1.07B USDFY2023 Net income: -6.58B USDFY2024 Free cash flow: -9.72B USDFY2024 Net income: -8.73B USDFY2025 Free cash flow: -5.32B USDFY2025 Net income: -3.67B USD
Free cash flow Net incomeProfit that arrives as cash stands level with net income; a gap year after year is worth reading about.

7 of 10

Filings

Every figure, the year it is for and the document it was read from.

SEC filingMarket data

The filed figures

Computed from the accounts this company filed with the SEC and, in a ratio with a price in it, the last close, dated on this page. Every filed figure below carries the fiscal year and the filing date its accounts were read from, and every blank carries the reason it is blank. Nothing here is a view on this company.

Universe Pharmaceuticals Inc.: the eight ratios, with the fiscal year and filing date behind each.
FigureValueYearAs of
n/mFY2025Oct 15, 2026
n/m Not meaningful for this company, such as a P/E on negative earnings or a bank's EV/EBIT.
n/aFY2025Oct 15, 2026
n/a A stored zero the filing does not prove, withheld rather than published as if it were a measurement.
n/aFY2025Oct 15, 2026
n/a The debt total on file was summed from short-term debt, long-term debt and lease obligations, and at least one of those was never captured. An absent term is spent as a zero inside that sum, and this balance sheet does not show the term is empty, so we will not build a leverage ratio, an enterprise value or a return on capital on it, or rank the company on one.
n/mFY2025Oct 15, 2026
n/m Not meaningful for this company, such as a P/E on negative earnings or a bank's EV/EBIT.
n/aFY2025Jan 29, 2026
n/a The debt total on file was summed from short-term debt, long-term debt and lease obligations, and at least one of those was never captured. An absent term is spent as a zero inside that sum, and this balance sheet does not show the term is empty, so we will not build a leverage ratio, an enterprise value or a return on capital on it, or rank the company on one.
n/aFY2025Oct 15, 2026
n/a The filed cash flow statement reports no dividend paid at all. That is not the same as a filed zero, and we will not read it as one.
n/aFY2025Jan 29, 2026
n/a The debt total on file was summed from short-term debt, long-term debt and lease obligations, and at least one of those was never captured. An absent term is spent as a zero inside that sum, and this balance sheet does not show the term is empty, so we will not build a leverage ratio, an enterprise value or a return on capital on it, or rank the company on one.
4.07FY2025Jan 29, 2026
n/aFY2025Oct 15, 2026
n/a A stored zero the filing does not prove, withheld rather than published as if it were a measurement.
n/mFY2025Oct 15, 2026
n/m Not meaningful for this company, such as a P/E on negative earnings or a bank's EV/EBIT.
0.54FY2025Oct 15, 2026
-2.26FY2025Jan 29, 2026
3/9FY2025Jan 29, 2026

The figures are computed from the accounts for fiscal 2025, the newest full year on file. 7 filed fiscal years on record, FY2019 to FY2025, from SEC EDGAR. Prices as of Oct 15, 2026. Ratios recomputed Oct 15, 2026. Two facts, because a recompute is not a fresh quote.

The year and the filing date name the statement each figure’s accounts are read from, and they stand even where the figure itself could not be computed: the line beneath a blank says what that statement did not carry. A figure’s name opens its formula and the filings behind it; a statement that names no SEC filing has no filing date, and reads n/a.

Ten years of filed figures, year by year

Ten years of filed figures

8 fiscal years, FY2018 to FY2025. 7 read from the annual reports Universe Pharmaceuticals Inc filed with the SEC, each naming its filing; the rest from statements that name none, which are market data. Amounts in USD, as reported.

Universe Pharmaceuticals Inc: revenue, earnings, free cash flow and returns, by fiscal year, with the filing each year was read from
YearRevenueOperating incomeNet incomeEPS, dilutedFree cash flowOperating marginReturn on equityFiling
FY202517.86B-2.92B-3.67Bn/a-5.32B-16.3%-6.5%20-F, Jan 29, 20260001213900-26-009000
FY202423.02B-8.02B-8.73Bn/a-9.72B-34.8%-19.2%20-F, Apr 29, 20250001213900-25-036798
FY202332.31B-3.97B-6.58Bn/a1.07B-12.3%-23.5%20-F, Jan 30, 20240001213900-24-007745
FY202240.1M-7.0M-7.9Mn/a-1.4M-17.5%-0.0%20-F, Feb 10, 20230001213900-23-010349
FY202148.0M13.6M11.3Mn/a-2.5M28.3%24.1%20-F, Jan 31, 20220001213900-22-004359
FY202030.7M10.3M7.6Mn/a6.1M33.4%36.3%20-F, Jan 31, 20220001213900-22-004359
FY201933.2M9.8M7.6Mn/a13.1M29.4%n/a20-F, Jan 31, 20220001213900-22-004359
FY201828.5M9.7M7.6Mn/a4.3M33.9%78.5%Market data, supplied Oct 15, 2026accession n/a
  • Revenue, compound annual growth FY2018 to FY2025: 150.9%
  • Earnings: Earnings was not positive in both 2018 and 2025, so a compound rate across the window is not defined. Both figures are in the table.
  • Earnings per share: Fewer than two filed years carry earnings per share.
  • Free cash flow: Free cash flow was not positive in both 2018 and 2025, so a compound rate across the window is not defined. Both figures are in the table.

Every figure in this section is a line of a filed annual statement or a ratio of two of them. Nothing here is estimated or smoothed. Earnings per share filed before a share split are put on today's share count, and say so. Nothing here is a verdict on the company.

8 of 10

Risks and guardrails

The accounting screens, the published tests, and the lines you can set to be told.

ComputedCompany statement

Universe Pharmaceuticals Inc: accounting screens and published tests, each with its source
FigureValue, source and document
Beneish M-score-2.26 ComputedFY2025 20-F, filed Jan 29, 2026, 0001213900-26-009000
Piotroski F-score3/9 ComputedFY2025 20-F, filed Jan 29, 2026, 0001213900-26-009000
Named tests met0 of 30 Computed
Beta3.24 ComputedClose of Oct 15, 2026

The named tests

Of 30 tests value investors published: 0 met, 19 not met, 11 we could not complete. Counts, never a score: a single figure would have to decide that meeting one investor’s criteria and meeting another’s are worth the same.

Which tests, by name(all 30)
Meets
None of the named tests.
Does not
Deep value; Large cap, low P/E; High F-score, low P/B (Joseph Piotroski); Three forensic scores; High returns and growth; Gross margin, turnover (Robert Novy-Marx); EV/EBITDA and coverage; High yield, low payout; Dividends and buybacks; Low beta, profitable; Near the 52-week low; Z-score and coverage (Edward Altman); High returns, low debt; Owner earnings yield; High return on tangibles; Low P/S, rising earnings (James O'Shaughnessy); Tangible book or below; Cash-flow yield and ROIC; Clean books, high ROIC
Not measured
Defensive investor (Benjamin Graham); Earnings yield and ROIC (Joel Greenblatt); Low PEG, low debt (Peter Lynch); ROIC at or above WACC; Two thirds of NCAV (Benjamin Graham); P/E times P/B (Benjamin Graham); Book or below, low debt (Walter Schloss); Cash-covered dividend; Cheapest quarter on P/E (David Dreman); Cheapest quarter on P/B (David Dreman); Low P/E, growth, yield (John Neff). A test with a figure we could not read is incomplete, never met and never failed.
Figures we could not read(19)
  • Debt to Equity: The debt total on file was summed from short-term debt, long-term debt and lease obligations, and at least one of those was never captured. An absent term is spent as a zero inside that sum, and this balance sheet does not show the term is empty, so we will not build a leverage ratio, an enterprise value or a return on capital on it, or rank the company on one.
  • Positive Earnings Streak: The latest filed year has no per-share earnings we can read; the test needs 10.
  • P/B Ratio: The stored figure is a zero that can stand for data we do not hold, so this test is not measured.
  • P/E Ratio: Earnings are zero or negative, so a price to earnings multiple is not meaningful. A negative P/E is not a cheap company and a large positive one from a near-zero denominator is not an expensive one.
  • EV/EBIT: The debt total on file was summed from short-term debt, long-term debt and lease obligations, and at least one of those was never captured. An absent term is spent as a zero inside that sum, and this balance sheet does not show the term is empty, so we will not build a leverage ratio, an enterprise value or a return on capital on it, or rank the company on one.
  • Return on Invested Capital: The debt total on file was summed from short-term debt, long-term debt and lease obligations, and at least one of those was never captured. An absent term is spent as a zero inside that sum, and this balance sheet does not show the term is empty, so we will not build a leverage ratio, an enterprise value or a return on capital on it, or rank the company on one.
  • PEG Ratio: Earnings are zero or negative, so a price to earnings multiple is not meaningful. A negative P/E is not a cheap company and a large positive one from a near-zero denominator is not an expensive one.
  • Eps Growth 5Y: We do not hold this figure for this company, so there is nothing to show.
  • EV/EBITDA: EBITDA is zero or negative, so a multiple of it is not meaningful.
  • Interest Coverage: Operating income is zero or below, so there is no operating profit to cover the interest bill and coverage is not meaningful (n/m).
  • Dividend Yield: We do not hold this figure for this company, so there is nothing to show.
  • Payout Ratio: We do not hold this figure for this company, so there is nothing to show.
  • Share Count Change Yoy: We do not hold this figure for this company, so there is nothing to show.
  • ROIC-WACC Spread: The debt total on file was summed from short-term debt, long-term debt and lease obligations, and at least one of those was never captured. An absent term is spent as a zero inside that sum, and this balance sheet does not show the term is empty, so we will not build a leverage ratio, an enterprise value or a return on capital on it, or rank the company on one.
  • Price To Ncav: We do not hold this figure for this company, so there is nothing to show.
  • Price To Graham: Earnings are zero or negative, so a price to earnings multiple is not meaningful. A negative P/E is not a cheap company and a large positive one from a near-zero denominator is not an expensive one.
  • P/S Ratio: The stored figure is a zero that can stand for data we do not hold, so this test is not measured.
  • Dividend Coverage Ratio: We do not hold this figure for this company, so there is nothing to show.
  • Dividend Streak: We do not hold this figure for this company, so there is nothing to show.

9 of 10

Declared positions

Whether anybody here owns this company.

Positions declared by the founder: no holding in any company shown here, as of October 3, 2026.

10 of 10

Next step

What to do with what you have read.

A thesis is your reason for owning it, in your words, with the figures that must stay true. Checking those figures every night against the newest filed accounts, and telling you once when one breaks, is what the subscription adds.

More on this company

What this cannot tell you

  • 19 figures could not be read on this company, among them Debt to Equity, Positive Earnings Streak, P/B Ratio. Each blank in the table above names the rest, with its reason. 11 named tests come back incomplete because of them, which is neither met nor missed.
  • We hold 7 filed fiscal years rather than 10, so the run above is shorter than a full decade and is counted as what it is.

And the one that is true of all of it: This is what the numbers say today. It cannot tell you the day one of them stops being true. Nothing here can, because the reasons are not written down.

Running this once is arithmetic on public documents and you are welcome to it. Writing down why you own each company, in your own words and with the numbers that have to stay true for it to hold, and then having those numbers re-checked every night against the newest filed accounts, and against the latest close where a rule watches a price, is Professional, the plan a new account starts on for 30 days, one trial per person. It writes to you the day one breaks, and stays quiet when nothing does. The check runs every night at 23:30 UTC. A filing is picked up the night after it is published.

Monitor my portfolioHow this is computed

No card. 30 free days, and nothing is charged unless you choose a plan.

Analyze your own portfolio

ValueScreener · valuescreener.ai · Computed from accounts filed with the SEC by this company, read from EDGAR, and from dated closing prices. On this page a filed figure opens into its formula, its inputs and the statement, fiscal year and filing date it was read from, and a price into the day of its close. A figure that cannot show that trail says so.

A computation on accounts filed with the SEC, not a recommendation and not advice. Past filings do not indicate future results. Risk disclaimer.

Margin Notes

Once a week, what changed in the filings of US-listed companies, why it can matter to a thesis, and what deserves a closer review. Grounded in filings, not market noise.

Site map

Apps

  • Android app coming soon
  • iPhone app coming soon
ValueScreener

Discover companies, research each one to its filings, track what matters, and take your work into your own spreadsheet.

ValueScreener is a trading name of Oliva Real Estate Technologies LLC, a Delaware limited liability company. Legal notices: legal@valuescreener.ai. © 2026 Oliva Real Estate Technologies LLC. All rights reserved.

Risk disclaimer. This service is provided for research and education only. Nothing on it is investment advice, a recommendation, or an offer to buy or sell any security. Capital is at risk, and past performance does not indicate future results. Figures come from filed accounts and may be incomplete, delayed or later restated, so verify a number against the filing before you act on it.

With your permission, Google Analytics, Microsoft Clarity and HubSpot set cookies to measure how this site and the product are used, including recordings of sessions. Nothing is set unless you allow it. Privacy policy